GW Pharma’s cannabis based epileptic drug on its way
22 october 2012 ; GW Pharmaceuticals, a drug manufacturing Biotech Company has been found to provide a significant and promising medication for treatment of epilepsy based on cannabis. This drug company has already commercialized its cannabis-based medication for treatment of multiple Sclerosis (MS).
The recent novel research studies carried out in animals has shown that cannabidivarin, a natural compound present in cannabis had the potential to suppress seizures in a wide range of research models afflicted with the detrimental epileptic condition. Ben Whalley, the lead researcher of the study said that the current study has proved to be an existing and a breakthrough investigation of the research group as it showed the involvement of the non-psychoactive constituents of the cannabis as an effective and a significant clinical option for treatment of the delirious epileptic illness. He also added that the current world is demanding for better clinical measures to cure epilepsy as these clinical needs are being unmet for many years. This clinical disorder is regarded to be associated with no treatment option and the available treatment options prove futile in more than one third of the people afflicted with this condition along with resulting in serious health complications as well as enhancing the cases of mortality. The common side effects of these anti-epileptic drugs those are usually prescribed to get rid of this detrimental health condition affect the cognitive as well as mental abilities in the patients.
This drug has also been found to work in conjugation with other clinical therapies and do not cause any clinical effect related to the primary metabolite of the cannabis. Jack is a Medical Student and a freelancer who is specialized in writing. He is associate with many Pharmacies for whom he writes articles based on generic drugs and general health related issues.
